# Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

> **NCT03013946** · PHASE3 · TERMINATED · sponsor: **AIO-Studien-gGmbH** · enrollment: 121 (actual)

## Conditions studied

- Renal Cell Carcinoma, Metastatic
- Renal Cell Cancer, Recurrent

## Interventions

- **BEHAVIORAL:** Concomitant coaching

## Key facts

- **NCT ID:** NCT03013946
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-18
- **Primary completion:** 2024-01-16
- **Final completion:** 2024-01-16
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** insufficient accrual rate
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013946, "Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03013946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*